These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15370250)

  • 21. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
    Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.
    Buske C; Dimopoulos MA; Grunenberg A; Kastritis E; Tomowiak C; Mahé B; Troussard X; Hajek R; Viardot A; Tournilhac O; Aurran T; Lepretre S; Zerazhi H; Hivert B; Leblond V; de Guibert S; Brandefors L; Garcia-Sanz R; Gomes da Silva M; Kimby E; Schmelzle B; Kaszynski D; Dreyhaupt J; Muche R; Morel P
    J Clin Oncol; 2023 May; 41(14):2607-2616. PubMed ID: 36763945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia.
    Tedeschi A; Ricci F; Goldaniga MC; Benevolo G; Varettoni M; Motta M; Pioltelli P; Gini G; Barate' C; Luraschi A; Vismara E; Frustaci AM; Nichelatti M; Vitolo U; Baldini L; Morra E
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):231-4. PubMed ID: 23490992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunoglobulin M 'Flare' after rituximab-associated acute tubular necrosis in Waldenström's macroglobulinemia.
    Izzedine H; Bourry E; Amrouche L; Brocheriou I; Uzunov M; Capron F; Leblond V; Deray G
    Int J Hematol; 2009 Mar; 89(2):218-222. PubMed ID: 19156501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thalidomide and rituximab in Waldenstrom macroglobulinemia.
    Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Briccetti FM; Pasmantier M; Zimbler H; Cooper RB; Moore M; Hill J; Rauch A; Garbo L; Chu L; Chua C; Nantel SH; Lovett DR; Boedeker H; Sonneborn H; Howard J; Musto P; Ciccarelli BT; Hatjiharissi E; Anderson KC
    Blood; 2008 Dec; 112(12):4452-7. PubMed ID: 18713945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Waldenström's macroglobulinemia].
    Poulain S; Wemeau M; Balkaran S; Hivert B; Hautecoeur A; Rossignol J; Fernandez J; Daudignon A; Roumier C; Soenen V; Lepelley P; Lai JL; Morel P; Leleu X
    Rev Med Interne; 2010 May; 31(5):385-94. PubMed ID: 20363537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Complete response achieved after rituximab plus CHOP therapy in a patient with rapidly progressing Waldenstrom's macroglobulinemia].
    Ise M; Sakai C; Kumagai K
    Rinsho Ketsueki; 2009 Jan; 50(1):34-8. PubMed ID: 19225227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.
    Treon SP; Branagan AR; Hunter Z; Santos D; Tournhilac O; Anderson KC
    Ann Oncol; 2004 Oct; 15(10):1481-3. PubMed ID: 15367407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.
    Weber DM; Dimopoulos MA; Delasalle K; Rankin K; Gavino M; Alexanian R
    Semin Oncol; 2003 Apr; 30(2):243-7. PubMed ID: 12720145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide.
    Dimopoulos MA; Hamilos G; Efstathiou E; Siapkaras I; Matsouka C; Gika D; Grigoraki V; Papadimitriou C; Mitsibounas D; Anagnostopoulos N
    Leuk Lymphoma; 2003 Jun; 44(6):993-6. PubMed ID: 12854900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia.
    Shaikh A; Habermann TM; Fidler ME; Kumar S; Leung N
    Clin Exp Nephrol; 2008 Aug; 12(4):292-295. PubMed ID: 18288560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.
    Dimopoulos MA; Hamilos G; Zervas K; Symeonidis A; Kouvatseas G; Roussou P; Gika D; Karmiris T; Bourantas K; Zomas A; Mitsouli C; Xilouri I; Vervessou E; Matsis K; Anagnostopoulos N; Economopoulos T;
    Ann Oncol; 2003 Aug; 14(8):1299-305. PubMed ID: 12881396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An unusual reoccurrence of Waldenstrom's macroglobulinemia as pleural effusions that had a discordant response with treatment.
    Amin CJ; Rabinowitz I
    Clin Lab Haematol; 2005 Jun; 27(3):200-2. PubMed ID: 15938727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens.
    Dimopoulos MA; Kastritis E; Delimpassi S; Zomas A; Kyrtsonis MC; Zervas K
    Haematologica; 2008 Sep; 93(9):1420-2. PubMed ID: 18641029
    [No Abstract]   [Full Text] [Related]  

  • 35. The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab.
    Weide R; Heymanns J; Köppler H
    Br J Haematol; 2000 Jun; 109(4):838-41. PubMed ID: 10929038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Durable complete remission after chemotherapy and rituximab in a case of Waldenström's macroglobulinemia with pleuropulmonary involvement.
    Capalbo S; Dargenio M; Delia M; Chiefa A; Diomede D; Napoli A; Ricco R; Liso V
    Ann Hematol; 2005 Sep; 84(9):625-6. PubMed ID: 15915349
    [No Abstract]   [Full Text] [Related]  

  • 37. Induction of complete haematological remission after monotherapy with anti-CD20 monoclonal antibody (RITUXIMAB) in a patient with alkylating agent resistant Waldenström's macroglobulinaemia.
    Weide R; Heymanns J; Köppler H
    Leuk Lymphoma; 1999 Dec; 36(1-2):203-6. PubMed ID: 10613467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study.
    Laszlo D; Andreola G; Rigacci L; Fabbri A; Rabascio C; Mancuso P; Pruneri G; Radice D; Pinto A; Frigeri F; Calabrese L; Billio A; Bertolini F; Martinelli G
    J Clin Oncol; 2010 May; 28(13):2233-8. PubMed ID: 20368573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment with Rituximab and Bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing-Neel syndrome.
    Varettoni M; Marchioni E; Bonfichi M; Picchiecchio A; Arcaini L; Arbasino C; Gotti M; Da Vià M; Delmonte M; Sciarra R; Cazzola M
    Am J Hematol; 2015 Aug; 90(8):E152-3. PubMed ID: 25975811
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.
    Ioakimidis L; Patterson CJ; Hunter ZR; Soumerai JD; Manning RJ; Turnbull B; Sheehy P; Treon SP
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):62-6. PubMed ID: 19362976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.